Leishmania are a genus of sandfly transmitted proto zoan parasites that cause a spectrum of debilitating and often fatal diseases in humans throughout the tropics and subtropics. The disease (termed leishmaniasis) torments over 12 million people worldwide, making 2.4 million people disabled and causing about 60,000 deaths annual ly. The WHO estimations show that 350 million people are thought to be at risk from the disease [1 3]. Although leishmaniasis is most common in tropical regions, it has also been diagnosed in overseas travelers and U.S. Gulf War veterans [4] and has emerged as an opportunistic infection of HIV patients [5] . The geographical distribu tion and pathology of leishmaniasis varies according to the species of the parasite. For instance, Leishmania donovani causes "visceral leishmaniasis" (also known as kala azar), characterized by an enlarged liver and spleen, that is often fatal, whereas L. major and L. tropica (in the Old World) and L. mexicana species complex, consisting of L. mexicana, L. amazonensis, and L. venezuelensis mostly (in the New World) cause "cutaneous leishmania sis" (known as oriental sore and characterized by self limiting skin lesions) [1] . This form is the most common leishmanial disease, and is often fairly mild in comparison to the others. Widespread, chronic, non ulcerative skin lesions resembling leprosy are indicative of "diffuse cuta neous leishmaniasis" [6, 7] that is commonly an effect of L. aethiopica (Old World) and L. mexicana species com plex (New World) infection. "Mucocutaneous leishmani asis" (or espundia) is due to L. (V.) braziliensis (Viannia subgenus) infection and most prevalent in Brazil, Bolivia, and Peru. It causes lesion in the mucous membranes, leading to devastation of tissues and extreme facial disfig urement [1, 8] . Secondary bacterial infections are com mon. Leishmania (L.) mexicana causes "Chiclero's ulcer", which can involve almost total destruction of the external ear.
BIOCHEMISTRY (Moscow) Vol. 76 No. 7 2011 system that is designed to destroy them. The majority of the current anti leishmanial drugs, such as Sb(V) based medications Pentostam and Glucantime or non antimo nial Amphotericin B, Paromomicin, and Miltefosine, seem to be inadequate due to factors such as cost, resist ance, and toxic side effects [10 14] . Thus, a vaccine that would protect the human host by annihilating the para sites upon transfer from the insect vector would be wel come. Several different designs have been recently explored [15] , but no generally applicable vaccine for leishmaniasis has yet come to light.
In principle, any unique feature Leishmania exposed on its cell surface could be investigated and exploited for the development of an anti leishmaniasis vaccine [16] . Leishmania are digenetic organisms that alternate between the insect vector and a mammalian host. The most abundant macromolecule on the surface of the insect infectious stage of all Leishmania species is a com plex glycoconjugate called lipophosphoglycan (LPG, see section "Cell Surface and Secreted Phosphoglycans of Leishmania"). Although killed or attenuated parasites did not result a valid vaccine [15, 16] , the LPG itself has been suggested to be a perspective vaccine candidate as the protective effect of the purified LPG fraction on mice challenged with L. major was demonstrated [17 19 ]. Here we discuss the preparation of synthetic neoglycoconju gates (neoglycoproteins and neoglycolipids) based on var ious elements of the LPG structure as potential anti leishmaniasis vaccines as well as the immunological eval uation for some of them.
GLYCOCONJUGATE SYNTHETIC VACCINES
The carbohydrate vaccine technology is an area developing rapidly because of modern bioconjugation techniques [20 22] , which allow an effective formation of carbohydrate-protein and carbohydrate-lipid conju gates. Traditional polysaccharide vaccines, i.e. highly purified immunogenic bacterial polysaccharides (usually capsular polysaccharides) [23, 24] , have been associated with the short duration of the induced immunity and proved to be poorly immunogenic in infants and young children [25, 26] . That happens because the polysaccha ride antigens are T cell independent: they induce an immune response without the involvement of T cells. The response lacks several important features that char acterize the T cell dependent immune response, such as immunological memory, an antibodies class switch from IgM to IgG, and affinity maturation [23] . Conjugation of the bacterial polysaccharide to an immunogenic protein carrier (detoxified versions of strongly immunogenic pro teins like diphtheria and tetanus toxins are often used) converts it to a T cell dependent antigen with enhanced immunogenicity. Thus, the new generation glycoconju gate vaccines against bacterial infections are immuno genic in infants and induce long lasting immunological memory resulting in a boostable response [27] . In 1990s, four anti meningitis glycoconjugate vaccines against Haemophilus influenzae b (Hib) were introduced with great result: the Hib induced meningitis has virtually been eradicated in countries with high immunization coverage [28] . Similarly, a tetravalent meningococcal glu coconjugate vaccine against Neisseria meningitidis serogroups A, C, Y, and W135 has recently been devel oped by Sanofi Pasteur and licensed in the USA [29] .
The glycan parts of modern glycoconjugate vaccines are, normally, native or functionalized bacterial capsular polysaccharides. These naturally derived carbohydrate polymers are heterogeneous mixtures that may include impurities and contaminants. The use of synthetic carbo hydrate structures, which can be chemically produced as single compounds in a controlled manner without batch to batch variability, can eliminate these problems. Recently, a fully synthetic hexasaccharide conjugated to keyhole limpet hemocyanin (KLH) was shown to be an effective vaccine against prostate cancer [30] . The methodology has been used by Verez Bencomo et al. [31] for the preparation of the first commercial synthetic anti meningitis glycoconjugate vaccine against Hib. The results of clinical testing in the target population demonstrated that the glycovaccine containing fully synthetic phospho glycans (which are fragments of capsular polysaccharides) is as effective as its natural counterpart. The vaccine was registered in Cuba in 2003 and is now part of the national immunization program. Similarly, a synthetic vaccine against Shigella dysenteriae type 1 based on a synthetic oligosaccharide conjugated to a protein was found to be more immunogenic than a glycoconjugate prepared from the native polysaccharide [32] . Synthetic preparation of the glycan part of the glycoconjugate vaccines also allows for chemical modifications of the structure that may not be possible to perform on the native material.
CELL SURFACE AND SECRETED PHOSPHOGLYCANS OF Leishmania
During the parasite life cycle, which involves a pro mastigote stage(s) in the midgut of the insect vector and an amastigote stage in the phagolysosomes of the mammalian macrophage, Leishmania survive and proliferate in highly hostile environments. Their survival strategies involve the formation of an elaborate and dense cell surface glycoca lyx composed of diverse stage specific glycoconjugates that form a protective barrier [33, 34] . Some of these macromolecules (including various phosphoglycans) were shown to be essential for virulence of the parasite [35 38] .
LPG is a predominant cell surface glycoconjugate of Leishmania promastigotes. Structurally, this is a poly(gly cosyl phosphate) consisting of the β Gal (1→4) α Man 1→OPO 3 repeating units (Fig. 1) , where the nature of the X and Y substituents varies according to the species. Leishmania donovani [34, 39] and L. infantum synthesize a linear phosphoglycan, whereas those of L. mexicana [40, 41] , L. major [42 44] , and L. aethiopica [45] have branched structures bearing non stoichiometric mono and/or disaccharide components (X) linked at O3 of the β D Galp residue. In L. major, the composition of the side chains varies and depends on the developmental stage of the parasite. In the LPG produced by L. aethiopi ca there are also some additional α D Manp residues (Y) linked to D mannose residues in the main chain. All LPG molecules are capped at the non reducing terminus with an oligosaccharide phosphate unit (basically, GalMan 3 phosphate, where some residues are non stoi chiometric; Fig. 1 ) and contain a glycan core (not shown) linked to an inositol phospholipid anchor [33, 38] at the reducing end of the chain. The cap oligosaccharide struc tures appeared to be species and stage specific: GalMan 3 and GalMan 2 caps have been found in L. donovani and L. mexicana LPG [33, 40, 47] , whereas for L. major LPG in promastigotes the cap was a Man 2 disaccharide [34, 42] and in amastigotes a GalMan disaccharide [34] .
In addition to cell surface LPG, Leishmania pro mastigotes produce a number of secreted glycoproteins, where a peptide core is modified (glycosylated) with LPG type phosphoglycans [47, 48] . Leishmania donovani secretes an acid phosphatase (sAP) in which the peptide chains are heavily glycosylated on C terminal serine/threonine domains. The glycans (which are, in fact, phosphoglycans) consist of the same disaccharide phosphate repeating units found in the corresponding LPG ( Fig. 1 ) and are phosphodiester linked to select ser ine residues [34] . All species of Leishmania promastigotes synthesize secreted filamentous proteophosphoglycan, which forms a highly viscous gel surrounding the parasite cells. Compositionally this proteophosphoglycan consists of 95% phosphoglycans in a species specific manner (Fig.  1 ). The poly(glycosyl phosphate) chains are attached to serine residues of the peptide component via phosphodi ester groups.
Hydrophilic phosphoglycans have been found in cul ture supernatants of Leishmania promastigotes and have been structurally characterized for L. major [49] , L. mex icana [50] , and L. donovani [51] . They are essentially the corresponding LPG molecules without the glycan coreinositol phospholipid region.
Leishmania mexicana amastigotes synthesize large amounts of a macromolecular amastigote specific pro teophosphoglycan and secrete it (in mg/ml concentra tions!) into the phagolysosome of the mammalian macrophage [46] . Some phosphoglycan chains are similar to those found in L. mexicana LPG, but the majority rep resent novel stage specific highly branched structures ( Fig. 1) , including (1→3) linked glucobiose and glu cotriose moieties and long phosphorylated side chains. The phosphoglycans are attached to serine residues of the protein backbone, most likely through the phosphate groups. The amastigote specific proteophosphoglycan is believed to activate the complement system via the man nose binding pathway. It may also contribute to the bind ing of Leishmania to host cells and play a role in modula tion of the biology of the infected macrophage [34] .
CHEMICAL SYNTHESIS OF PHOSPHOGLYCANS OF Leishmania DESIGNED FOR FURTHER BIOCONJUGATION
The most distinctive part of Leishmania LPG is their variable phosphoglycan domain, made of β Gal (1→4) α Man 1→OPO 3 phosphodisaccharide repeats linked to each other through a phosphodiester group between the anomeric hydroxyl of D mannose of one repeat and the 6 OH group of D galactose of the adjoining repeat (see section "Cell Surface and Secreted Phosphoglycans of Leishmania"). The preparation of neoglycoconjugates based on phosphosaccharide repeats upholds the need to develop routes for the chemical synthesis of Leishmania phosphoglycans. The development of synthetic approaches to phosphoglycans is challenging, because the phosphoglycans are hydrolytically labile due to anomeric phosphodiester linkage present between the repeating units. Synthesis of anomeric phosphodiesters is compli cated, as both the correct stereochemistry at C1 and the lability of anomeric phosphodiester linkages must be taken into consideration [52, 53] .
The first successful syntheses of Leishmania phos phoglycans were achieved by the Dundee University group [54 56] by exploiting the H phosphonate chem istry. The glycosyl H phosphonate route was proven to be the method of choice for the efficient and reliable assem bly of various phosphodiester linkages characteristic of natural phosphoglycans [53] . The L. donovani phospho glycans 1 5 (linear chains, built up from disaccharide phosphate repeating units in (1→6) phosphodiester link age and varying in length and by the presence of the Man 2 phosphate cap in 4 and 5; Fig. 2 ) were constructed in a stepwise (1 4) [54, 55] and a blockwise (5) [56] chain elongation manner.
All the prepared phosphoglycans contain a dec 9 enyl aglycone moiety as they were purposely designed [55] for (a) studying Leishmania biosynthetic enzymes and (b) further preparation of neoglycoconjugates, which could be tested as potential anti leishmaniasis vaccines. The hydrophobicity of the dec 9 enyl chain has been exploited for assaying, first, the mannosylphosphate transferases [57, 58] and then the galactosyltransferases [59, 60] involved in the LPG biosynthesis in Leishmania. As for the bioconjugation, the high lability of the anomer ic phosphodiester bridges in phosphoglycans was given the top priority while selecting techniques for the neogly coconjugate preparation. It was decided to avoid the use of any condensing reagents (which could easily interfere with the phosphate groups and facilitate the cleavage of the glycosyl phosphate bonds) and profit from the ozonolysis of the double bond in the dec 9 enyl aglycone linker instead, thus transforming it into an aldehyde func tionality, which could be coupled to a protein or a lipid carrier by reductive amination (see section "The Preparation of Neoglycoconjugates Based on Phosphosaccharide Repeats Using Ozonolysis/Reductive Amination Technique").
The branched heptaglycosyl triphosphate phospho glycan 6 (Fig. 3) from L. mexicana (containing β D glu cose moiety in the side chain) was assembled via step wise chain elongation [61] . A matching strategy was employed in the synthesis of the branched phosphogly cans 7 9 [62, 63] (Fig. 3) .
Polymer supported synthetic methodologies [66, 67] that employed glycosyl H phosphonates for consecutive chain elongation have been also successfully developed for the preparation of Leishmania phosphoglycans as well as the H phosphonate polycondensation strategy [67, 68] .
THE PREPARATION OF NEOGLYCOCON JUGATES BASED ON PHOSPHOSACCHARIDE REPEATS USING OZONOLYSIS/REDUCTIVE AMINATION TECHNIQUE
As mentioned above, all the phosphoglycans designed and synthesized in Dundee were equipped with a dec 9 enyl aglycone linker to enable their future incorporation into neoglycoconjugates via oxidation of the terminal double bond. Ozonolysis of the phosphoglycans in methanolic solution afforded the corresponding 8 car bonyloctyl glycosides (or phosphosaccharide 8 carbonyl octyl diesters; Fig. 4 ), which were immediately used for coupling with a protein (or a lipid) carrier by reductive amination with NaCNBH 3 ([69, 70] and Sizova, O. V., Nikolaev, A. V., and Ferguson, M. A. J., unpublished data). The conversion of the phosphoglycans to their 8 carbonyloctyl derivatives was shown to be complete and proceeds without destruction of the labile anomeric phos phodiesters [69] . Ozonolysed compounds were mixed with NaCNBH 3 and a protein in a phosphate buffer solu tion to obtain a molar ratio of phosphosaccharide/protein NH 2 group/NaCNBH 3 of 1 : 3 (if another one is not spec ified) : 50. The prepared neoglycoconjugates were puri fied by gel filtration on a column of Superdex 200 HR (Amersham Biosciences, USA). Fractions containing the product were concentrated using ultrafiltration technique and Amicon centrifugal filters (Millipore, USA) (see the experimental procedures below). Following SDS PAGE analysis showed that no starting protein was observed [69, 70] .
To develop the optimal conjugation conditions, first [69] , the L. donovani phosphoglycan 4 ( Fig. 2) was ozono lysed and coupled to ribonuclease A (RNase A; M = 13,690 Da, 10 amino groups) using a molar ratio of phos phosaccharide/protein amino group of 1 : 5. That gave a glycoconjugate containing 1.1 phosphosaccharide (hap ten) chains per RNase A molecule (i.e. one chain of a hap ten per 12,440 Da of protein). The ozonolysed disaccha ride phosphate 1 (Fig. 2 ) was coupled to BSA as a carrier (M = 66,382 Da, 59 amino groups) using a molar ratio of phosphosaccharide/protein amino group of 1 : 1, thus pro ducing a glycoconjugate containing eight hapten chains per molecule of BSA (i.e. one chain of a hapten per 8,300 Da of protein). Although this was around three fold lower than that reported for oligosaccharide-BSA conju gates prepared using similar reductive amination tech niques [71, 72] , in the latter cases a large molar excess of oligosaccharide over BSA amino groups (about 200 : 1) was used. Since (a) the synthetic phosphoglycans are rather precious and (b) a relatively low hapten/protein ratio (like one chain of a hapten per 10 kDa of protein) may be desir able from an antigen presentation point of view [69] , the developed conditions were used for the preparation ( [70] and Sizova, O. V., Nikolaev, A. V., and Ferguson, M. A. J., unpublished data) of Leishmania phosphoglycan-tetanus toxin fragment C conjugates 13 19 (Fig. 4) .
The engineered tetanus toxin fragment C (TetC) [73] does not retain any toxicity, but it retains immunogenici ty [74] . It was already tested on the vaccine market [75] and has the advantage of inducing a Th 1 response that is necessary for the killing Leishmania parasites [76, 77] . The synthetic phosphoglycans were coupled to TetC using a molar ratio of phosphosaccharide/protein amino group of 1 : 3 [69, 70] branched L. mexicana phosphoglycan 6 (Fig. 3) , followed by protein coupling produced the L. mexicana-TetC gly coconjugate 16, while the L. major-TetC glycoconjugates 17 and 18 were generated from the L. major phosphogly cans 9 and 12 ( Fig. 3) , respectively. The prepared conju gates were carrying from 3.37 to 4.85 phosphosaccharide haptens per molecule with, on average, one chain of a hapten per 13,300 Da of protein. The SDS PAGE analy sis of the prepared neoglycoproteins showed that no start ing TetC protein was observed (Fig. 5) .
The modified L. donovani-TetC glycoconjugates 19a and 19b (Fig. 4) were prepared from the synthetic C glycosyl phosphono analogue of the LPG fragment with a structure of β Gal (1→4) α Man (1→CH 2 PO 2 H 6) β Gal (1→4) α Man 1→CH 2 PO 2 H O(CH 2 ) 8 CH=CH 2 21 [78] . Replacing the anomeric O1 in D mannose residues with CH 2 groups in 21 does not, probably, change much conformation of the molecule, but makes the C glycosyl phosphono analogues significantly more stable chemically than parent phosphoglycans and resists the action of phosphatases as well. All of those make the phosphono analogues of the parasitic and bacteria phos phoglycans strong candidates for synthetic glycoconju gate vaccines [79, 80] . Ozonolysis of compound 21, fol lowed by coupling to TetC with a molar ratio of phospho nosaccharide/protein amino group of 1 : 3 furnished the glycoconjugate 19a containing just two hapten chains per molecule, while the higher loaded conjugate 19b (with 9.7 hapten chains per molecule; Fig. 5 ) was prepared using a higher molar ratio of the phosphonosaccharide over TetC amino groups of 2 : 3.
Finally, the neoglycolipid 20 (Fig. 4) was synthesized [69] by coupling the ozonolysed phosphoglycan 4 and 1,2 di O hexadecyl sn glycero 3 phosphatidylethanol amine in a mixture of chloroform-methanol-water using a molar ratio of phosphosaccharide/amine/NaCNBH 3 of 1 : 20 : 50. After purification on an Octyl Sepharose col umn followed by Kieselgel 60, the glycoconjugate was iso lated in 36% yield. For immunological studies, the neo glycolipids could be incorporated into liposomes that act as a carrier and as an adjuvant [81] .
Experimental procedures for the preparation of neo glycoproteins 13 19 ([70] and Sizova, O. V., Nikolaev, A. V., and Ferguson, M. A. J., unpublished data). Ozonolysis of phosphosaccharides. Synthetic phosphosaccharides 2 4, 6, 9, 12, or 21 (as their ammonium or triethylammoni um salts; 0.3 0.6 mg of a phosphosaccharide in one experiment) were dissolved in 1 ml of methanol or a mix ture of methanol-water (5 : 1). The solution was cooled to -78°C and ozone (from ozone generator OZ06; Peak Scientific Ltd., Scotland) was bubbled (~5 min) into it via a sintered glass bubbling tube until a pale blue colour per sisted. Oxygen was then bubbled (~10 min) through the solution until it became colorless to eliminate excess O 3 . Dimethylsulfide (0.01 ml) was added to reduce the ozonide, and the solution was allowed to warm to room temperature and left for 2 h. The products (corresponding 8 carbonyloctyl phosphosaccharides) were dried by evap 
Coupling of phosphosaccharides to TetC and rapid purification of neoglycoconjugates. The prepared 8 car bonyloctyl phosphosaccharides and NaCNBH 3 were dis solved in 0.1 M phosphate buffer (0.54 0.70 ml, pH 7.4) and added to a TetC solution (0.06 0.15 ml) in the same buffer to obtain a molar ratio of phosphosaccharide/pro tein amino group/NaCNBH 3 of 1 : 3 : 50 (for the prepa ration of the glycoconjugate 19b only, the ratio was taken as 2 : 3 : 50.) The mixture was incubated at 37°C for 72 h and then centrifuged at 13,000 14,000 rpm (30 min, 4°C). The prepared neoglycoproteins stayed in the super natant solution and were purified by gel filtration on a column of Superdex 200 HR (void volume 8.5 ml) using 0.1 M phosphate buffer, pH 7.2, as eluant at a flow rate of 0.5 ml/min. Neoglycoproteins were detected with a UV detector at 280 nm; eluate of 1 min was collected into each tube. For each coupling experiment, the elution profile appeared to be as a single or one major peak, elut ing in the area between 25 and 33 min. The appropriate fractions were combined (the total volume of the peak was about 2 3 ml). The glycoconjugate solutions were con centrated by ultrafiltration (5,000g, 30 min, 4°C) using an Amicon Ultra 0.5 Centrifugal Filter (Millipore) with an Ultracel 30 Membrane (30 kDa nominal molecular weight limit) and an Avanti centrifuge (Beckman, USA), thus providing samples of neoglycoproteins 13 19 in phosphate buffered saline (volume of each sample 0.30 0.89 ml; protein concentration 1.13 4.28 mg/ml). The following SDS PAGE analysis of the samples showed that no starting TetC protein was observed (Fig. 5) .
Oligosaccharide concentrations were determined by phenol-sulfuric acid assay [82] performed in triplicate. Protein concentrations were determined by the bicin choninic acid assay (Pierce, USA) according to the man ufacturer's instructions. SDS PAGE was performed for native and coupled (to phosphosaccharides) TetC using 8% gel and the discontinuous buffer system of Laemmli [83] . Gels were stained with Coomassie blue to detect protein bands. [84] . Intriguingly, only the L. mexicana-TetC glycovaccine 16 showed significant protection compared with the control TetC immunization, resulting in a 50% reduction in lesion size and a 94% (!) reduction in para site burden. The other glycovaccines 14, 17, and 18, nei ther the L. mexicana phosphoglycan 6 (Fig. 3 ) alone, were unable to provide protection against infected fly bite chal lenge. Thus, that was the first (to the best of the authors [84] knowledge) demonstration that a synthetic glyco conjugate vaccine can have a direct antiparasite effect in leishmaniasis or any other parasitic disease. It seems that these glycovaccines may induce species and glycan struc ture specific protection, although the ability of the L. mexicana-TetC glycovaccine 16 to protect against other species of Leishmania has not been tested yet.
IMMUNOLOGICAL STUDIES OF

THE PREPARATION OF NEOGLYCOCON JUGATES BASED ON THE TETRASACCHARIDE CAP STRUCTURE
The Cambridge (Massachusetts, USA) group [16, 85] has designed and synthesized two potential Leishmania vaccine constructs based on a structure of the tetrasaccharide phosphate cap (GalMan 3 phosphate) of LPG, while the phosphate group being omitted thus sim plifying strongly the conjugation technique (see section "Chemical Synthesis of Phosphoglycans of Leishmania Designed for Further Bioconjugation"). Chemically pre pared tetrasaccharide 22 (Fig. 6 ) was equipped with a 6 aminohexyl aglycone linker to facilitate further bioconju gation. The GalMan 3 tetrasaccharide itself has previously been a subject of two synthetic approaches [86, 87] .
Two neoglycoconjugates 25 and 28 ( Fig. 6) were pre pared by joining the tetrasaccharide antigen 22 with pro tein carrier KLH or with lipid immunostimulator tri palmitoyl S glycerylcysteine 27, respectively. The KLH proteins are known to be highly heterogeneous and have enormous molecular masses (4,500 13,000 kDa) as well as ill defined structures, but their immunogenic capabili ties can be superior [88] . Prior to the conjugation, the protein itself was reacted with N succinimidyl bromoac etate to form the N (bromoacetyl) modified carrier 26, while the 6 aminohexyl tetrasaccharide 22 was coupled with pentafluorophenyl (acetylsulfanyl)acetate 23 to give the tetrasaccharide 24 with masked SH functionally in the linker. Further coupling of 24 with the modified pro tein 26 in the presence of hydroxylamine was followed by capping of any remaining bromoacetyl groups with 2 aminoethanethiol to furnish the neoglycoprotein 25, which was purified by gel filtration on a Pd 10 column (Sephadex G 25). The reported conjugation ratio of the GalMan 3 hapten chains to each KLH molecule was 55 : 1 (which is about one chain of the tetrasaccharide hapten per 82,000 236,000 Da of protein).
The lipopeptide N palmitoyl S [(2R,2S) 2,3 di(palmitoyloxy)propyl] L cysteine 27 (tripalmitoyl S glycerylcysteine, Pam 3 Cys) has been already reported as a part of a fully synthetic vaccine [89] . It can work both as a carrier and an adjuvant [90] and is readily available by synthesis [91] . Coupling of lipopeptide 27 with the 6 aminohexyl tetrasaccharide 22 was performed in the pres ence of HATU and diisopropylethylamine and afforded the neoglycolipid 28 (60%) after purification on a silica column. Both synthetic glycovaccines have been tested for their immunological evaluation in BALB/c mice, but the results have not been reported yet.
FUTURE ADVANCES
Despite appreciable progress in the preparation of neoglycoconjugates based on synthetic cell surface struc tures of Leishmania, there are still several unresolved issues that prevent the neoglycoconjugates from being routinely synthesized to furnish further immunological testing. Part of them is dealing with rapid and effective preparation of synthetic LPG fragments and, therefore, novel methods towards anomeric phosphodiesters are in demand. This may also include a search for novel activat ing (for the H phosphonate condensation) and oxidizing reagents. The oxidation step appeared to be a problem for the preparation of some sterically hindered glycosyl phos phosaccharides [52, 53] as the intermediate H phospho nic diester, instead of its smooth transformation to the phosphodiester, may undergo hydrolysis of the glycosidic linkage as a concurrent reaction.
We have already cited in the introduction to this review that any unique feature Leishmania expose on its cell surface could be investigated and exploited for the development of an anti leishmaniasis vaccine [16] . As all LPG molecules contain at the reducing end of the chain a glycan core of the α Gal (1→6) α Gal (1→3) β Galf (1→3) [α Glc 1→PO 3 H 6)] α Man (1→3) α Man (1→4) α GlcNH 2 structure, which, in turn, is (1→6) linked to a 1 O alkyl(C 24 26 chain) 2 lyso phosphatidyl myo inositol lipid anchor [33, 38] , it seems valuable to prepare neoglycoconjugates based on the above structure. The preparation of the glycan core myo inositol conju gate has been recently reported [92, 93] .
LPG molecules are expressed on the promastigote (i.e. insect's midgut stage) membrane of all species of Leishmania [33, 40, 94] , while their expression in amastigote parasites (existing in human phagolysosomes) significantly decreases, with an exception of L. major amastigotes [95] . At this stage, small molecules called glycoinositolphospholipids, which structures are, in some extent, similar to the above heptasaccharide glycan core (or part of it) linked to an inositolphospholipid anchor [33, 38, 44] , remain the dominant surface structures. Thus, it looks worthy to prepare neoglycoconjugates based on the glycoinositolphospholipid structures and test them as potential anti leishmaniasis vaccines.
We are indebted to Prof. M. A. J. Ferguson (Dundee University) for his interest, constant support, and encouragement. Tetanus toxin fragment C (TetC) was a generous gift from Prof. C. Watts (Dundee University). Financial support from the Royal Society (6 month Traveling Fellowship to the United Kingdom for O. V. S.) and the Wellcome Trust grant 083481 (for the infrastruc ture maintenance of the Division of Biological Chemistry and Drug Discovery within the University of Dundee) is gratefully acknowledged.
